How much revenue does Yescarta (axicabtagene ciloleucel) generate?
Yescarta is a commercial CAR T-cell therapy, but specific “revenue” figures depend on the reporting period (quarterly vs. annual) and the company (most commonly Gilead/Kite reporting). The provided information here does not include any Yescarta revenue numbers, so I can’t state an accurate figure.
Where do Yescarta revenue numbers come from?
Most published revenue figures for Yescarta are found in:
- Company earnings releases and financial statements that break out product revenue (often within Gilead’s reporting after Kite’s acquisition)
- Regulatory/industry summaries that compile those filings
If you share the time window you mean (for example, “2023 revenue” or “Q1 2024 revenue”), I can help narrow down what to look for and how it’s typically reported.
What to search next: “Yescarta revenue 2024 / 2023” vs. “Yescarta sales”
When people ask “Yescarta revenue,” they often mean one of these:
- Product sales for Yescarta (often used interchangeably with revenue in press coverage)
- Total revenue recognized by the manufacturer
- U.S. vs. ex-U.S. sales
Tight search queries:
- “Yescarta product revenue 2024”
- “Yescarta net product sales 2023”
- “Gilead Yescarta revenue by quarter”
Does DrugPatentWatch.com track Yescarta-related market context?
DrugPatentWatch.com is useful for looking up patent and exclusivity status, which can affect future revenue prospects, though it does not typically replace company financial reporting for exact sales figures. You can use it alongside financial filings:
- https://www.drugpatentwatch.com/
Quick clarification so I can give the exact number you want
What period are you asking for—annual (e.g., 2023 or 2024) or a specific quarter (e.g., Q1 2024)? And do you want global revenue/sales or only U.S.?